NASDAQ:OGI

OrganiGram Stock Forecast, Price & News

$1.74

-0.06 (-3.33 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.70

Now: $1.74▼

$1.81

50-Day Range

$1.29

MA: $1.51▼

$1.83

52-Week Range

$1.01

Now: $1.74▼

$3.04

Volume10.09 million shs

Average Volume14.97 million shs

Market Capitalization$403.83 million

P/E RatioN/A

Dividend YieldN/A

Beta0.3

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

MarketRank^™

Overall MarketRank^™

1.58 out of 5 stars

Medical Sector

322nd out of 1,926 stocks

Pharmaceutical Preparations Industry

168th out of 773 stocks

4.2 Analyst's Opinion

Consensus Rating
OrganiGram has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.64, OrganiGram has a forecasted upside of 52.0% from its current price of $1.74.
Amount of Analyst Coverage
OrganiGram has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
OrganiGram has received 183 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
OrganiGram has received 114 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
OrganiGram has received 61.62% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote “Outperform” if you believe OGI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
OrganiGram does not currently pay a dividend.
Dividend Growth
OrganiGram does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OrganiGram insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 10.84% of the stock of OrganiGram is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for OrganiGram are expected to grow in the coming year, from ($0.11) to ($0.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OrganiGram is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OrganiGram is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OrganiGram has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OGI

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.organigram.ca

Phone1-855-961-9420

Employees517

Debt

Debt-to-Equity Ratio0.17

Current Ratio2.66

Quick Ratio3.39

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$64.61 million

Price / Sales6.25

Cash Flow$0.02 per share

Price / Cash Flow101.50

Book Value$1.04 per share

Price / Book1.67

Profitability

EPS (Most Recent Fiscal Year)($0.08)

Net Income$-101,290,000.00

Net Margins-207.26%

Return on Equity-10.00%

Return on Assets-7.14%

Miscellaneous

Outstanding Shares232,088,000

Market Cap$403.83 million

Next Earnings Date4/13/2021 (Estimated)

OptionableNot Optionable

$1.74

-0.06 (-3.33 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

How has OrganiGram's stock been impacted by COVID-19?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OGI shares have increased by 1.2% and is now trading at $1.74.
View which stocks have been most impacted by COVID-19.

Is OrganiGram a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as OrganiGram's CEO?

1,448 employees have rated OrganiGram CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among OrganiGram's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) announced its quarterly earnings data on Monday, November, 30th. The company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.03). The business earned $15.19 million during the quarter, compared to the consensus estimate of $14.77 million. OrganiGram had a negative net margin of 207.26% and a negative return on equity of 10.00%.
View OrganiGram's earnings history.

What price target have analysts set for OGI?

12 brokers have issued 12 month price targets for OrganiGram's shares. Their forecasts range from $1.72 to $4.00. On average, they anticipate OrganiGram's share price to reach $2.64 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts' price targets for OrganiGram or view Wall Street analyst' top-rated stocks.

Are investors shorting OrganiGram?

OrganiGram saw a decline in short interest in December. As of December 31st, there was short interest totaling 12,820,000 shares, a decline of 19.4% from the December 15th total of 15,910,000 shares. Based on an average daily volume of 7,640,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 5.6% of the company's stock are sold short.
View OrganiGram's Short Interest.

Who are some of OrganiGram's key competitors?

Some companies that are related to OrganiGram include Heron Therapeutics (HRTX), Rhythm Pharmaceuticals (RYTM), Nkarta (NKTX), Endo International (ENDP), COMPASS Pathways (CMPS), Arcturus Therapeutics (ARCT), Zealand Pharma A/S (ZEAL), Supernus Pharmaceuticals (SUPN), Ocular Therapeutix (OCUL), ImmunoGen (IMGN), Amneal Pharmaceuticals (AMRX), Repare Therapeutics (RPTX), Cytokinetics (CYTK), DiaMedica Therapeutics (DMCAF) and Mersana Therapeutics (MRSN).
View all of OGI's competitors.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:

Mr. Gregory Engel, CEO & Director (Age 55)
Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 53)
Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 47)
Mr. Matt Rogers, Sr. VP of Operations
Amy Schwalm, VP of Investor Relations
Ms. Helen Martin, Sr. VP of Strategic & Legal Affairs and Company Sec. (Age 42)
Mr. James Cavanagh, Chief of Staff
Mr. Larry Rogers, VP of International Bus. Devel.
Mr. Peter R. Hanson, Director of Fin.

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.74.

How big of a company is OrganiGram?

OrganiGram has a market capitalization of $403.83 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. OrganiGram employs 517 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here